Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment

Okumura, Lucas Miyake; Antunes, Valquíria D.; Aguiar, Karina S.; Farias, Tatiane; Andrzejevski, Vânia Mari Salvi; Funke, VAM

doi:10.18549/pharmpract.2015.02.559

Cited by 7 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Student’s t-test was used to evaluate the significance of differential expression of RNAs between samples of OA associated with mild pain and severe pain. Considering the small sample sizes, the RNAs were selected with P <0.2 as the differentially expressed RNAs [28,29]. Also, the edges were extracted that were related to differentially expressed RNAs and the differential expression subnetwork was constructed of the lncRNA-associated ceRNA network in OA (Supplementary Table 2, available on request from authors).…”

Section: Methodsmentioning

confidence: 99%

A Long Noncoding RNA (lncRNA)-Associated Competing Endogenous RNA (ceRNA) Network Identifies Eight lncRNA Biomarkers in Patients with Osteoarthritis of the Knee

et al. 2019

View full text Add to dashboard Cite

Background Osteoarthritis (OA) of the knee is a common disease that is associated with chronic pain. This study aimed to identify and investigate the functional role of biomarkers associated with long noncoding RNA (lncRNA) in the progression of OA of the knee by lncRNA-associated competing endogenous RNA (ceRNA) integrated network analysis. Material/Methods High-quality microRNA (miRNA)-lncRNA and miRNA-mRNA interactions and lncRNA and mRNA expression profiles for patients with OA of the knee with mild and severe pain were obtained from the Gene Expression Omnibus (GEO) database (GSE99662). A three-step computational method was used to construct the lncRNA-associated ceRNA interaction network in OA by integrating miRNA-lncRNA/mRNA interactions and lncRNA/mRNA expression profiles in patients with OA with mild and severe pain. Results A total of 1,870 dysregulated lncRNA-mRNA interactions were obtained in the lncRNA-associated ceRNA network in OA, including 476 gain and 1,394 loss interactions, covering 131 lncRNAs and 1,251 mRNAs. Characterization of the lncRNA-associated ceRNA network in OA indicated that lncRNAs had roles in the network. Further differential expression analysis identified eight lncRNA biomarkers, which could distinguish between patients with OA with mild pain and severe pain. These lncRNA-associated interactions showed significantly different co-expression patterns in samples from patients with OA of the knee associated with mild pain. Conclusions Integrated network analysis of lncRNA-associated ceRNA identified eight lncRNA molecular biomarkers associated with the progression of OA of the knee.

show abstract

Section: Methodsmentioning

confidence: 99%

A Long Noncoding RNA (lncRNA)-Associated Competing Endogenous RNA (ceRNA) Network Identifies Eight lncRNA Biomarkers in Patients with Osteoarthritis of the Knee

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Patient adherence to treatment (considered to be approximately 80-95% of doses taken as intended) is associated with deeper molecular responses, whereas non-adherence has been associated with poorer eventfree survival. [14][15][16][17][18][19][20][21] Poor treatment adherence can also lead to progressive, more difficult to treat disease, increased symptom severity, decreased quality of life, and greater healthcare costs. 14,[16][17][18]66 Unintentional non-adherence may occur as a result of AEs or drug-drug interactions between TKI treatment and concomitant medications.…”

Section: Treatment Adherencementioning

confidence: 99%

“…[14][15][16][17][18][19][20][21] Poor treatment adherence can also lead to progressive, more difficult to treat disease, increased symptom severity, decreased quality of life, and greater healthcare costs. 14,[16][17][18]66 Unintentional non-adherence may occur as a result of AEs or drug-drug interactions between TKI treatment and concomitant medications. Drug-drug interactions could potentially lead to increased or decreased systemic levels of TKIs and have negative impact on the efficacy and safety of the CML treatment, essentially leading to patient non-adherence to therapy.…”

Section: Treatment Adherencementioning

confidence: 99%

“…8,14 Poor treatment adherence in CML has been associated with the inability to achieve adequate molecular responses and with poorer treatment outcomes. [14][15][16][17][18][19][20][21] Given the availability of multiple first-line TKIs, patients and providers have the opportunity to individualize initial treatment approaches. The involvement of pharmacists is critical to ensure a successful oncology care team, as they play an important role in treatment selection, identification, and management of adverse events (AEs), monitoring drug-drug interactions, patient education, medication adherence, and cost-effectiveness.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Front-line use of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: Practice considerations

Reff¹,

Shillingburg

Shah

et al. 2019

J Oncol Pharm Pract

View full text Add to dashboard Cite

The development of BCR-ABL-targeting tyrosine kinase inhibitors has transformed chronic phase chronic myeloid leukemia (CP CML) from a disease with a terminal prognosis to a treatable chronic illness. Long-term treatment with tyrosine kinase inhibitors means that patients have to be clinically managed and monitored over extended periods of time, thus a patient-centered, medically integrated, and multidisciplinary oncology healthcare team is required to support patients through their journey. Pharmacists work with patients, physicians, and the wider support team to select the optimum therapy plan for a given patient. These decisions are based on risk factors, comorbidities, concomitant medications, and personal circumstances and pharmacists advise on the efficacy and safety of different treatment options. Additionally, pharmacists are a key point-of-contact and resource for monitoring patient response to treatment, identifying and managing adverse events and drug–drug interactions, any subsequent therapy plan modifications, and, potentially, treatment-free remission. Pharmacists also assist with patient education, medication adherence, and financial discussions with patients throughout the long course of the disease. This review provides an overview of BCR-ABL tyrosine kinase inhibitors, discusses the role of the medically integrated pharmacy team, and suggests strategies that pharmacists can use in patient management and clinical decision-making to optimize the treatment of CP CML.

show abstract

“…13 Additional factors, such as trust of prescribing provider, impact of medication on lifestyle, cost of medication, and social support, have also been identified as being associated with adherence to oral therapy. 14–17…”

Section: Introductionmentioning

confidence: 99%

Impact of dosing frequency (once daily or twice daily) on patient adherence to oral targeted therapies for hematologic malignancies: a retrospective cohort study among managed care enrollees

Patel

Sudhir²,

Kabadi

et al. 2019

J Oncol Pharm Pract

View full text Add to dashboard Cite

PurposeExisting studies evaluating patient adherence to oral targeted therapies such as tyrosine kinase inhibitors focus on small populations with single malignancies. This study evaluated patterns of use of oral agents in a larger population across multiple hematologic malignancies.MethodsAdult patients diagnosed with a hematologic malignancy and prescribed oral targeted therapy between 2011 and 2016 (N = 18,976) were identified from the MarketScan Commercial Claims and Encounters, and Medicare Supplemental databases. Eligible patients were enrolled in monthly prescription plans 6 months before and 12 months after the index date (date of first prescription claim; n = 2442). Multivariable logistic regressions were used to determine predictors of adherence using the medication possession ratio (MPR) and persistence through prescription refill gaps.ResultsThe overall median adherence was 0.9 (MPR ≥ 80%) and was comparable between once-daily (QD) and twice-daily (BID) groups. Overall, 59% of patients were persistent at 12 months. Patients on QD and BID products did not have any significant differences in adherence (fixed-interval MPR, odds ratio 0.94; 95% confidence interval (CI), 0.75–1.18) or persistence (odds ratio 0.93; 95% CI, 0.75–1.17) 12 months from index. Significant predictors of adherence and persistence included patient age, total inpatient admissions, number of adverse events, and total hospital visits.ConclusionPatient-specific clinical factors, rather than regimen-specific factors, were the main predictors of oral targeted therapy adherence and persistence. Adherence to oral targeted therapies appears to be similar for patients on QD and BID regimens in the real-world setting.

show abstract

Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment

Cited by 7 publications

References 22 publications

A Long Noncoding RNA (lncRNA)-Associated Competing Endogenous RNA (ceRNA) Network Identifies Eight lncRNA Biomarkers in Patients with Osteoarthritis of the Knee

A Long Noncoding RNA (lncRNA)-Associated Competing Endogenous RNA (ceRNA) Network Identifies Eight lncRNA Biomarkers in Patients with Osteoarthritis of the Knee

Front-line use of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: Practice considerations

Impact of dosing frequency (once daily or twice daily) on patient adherence to oral targeted therapies for hematologic malignancies: a retrospective cohort study among managed care enrollees

Contact Info

Product

Resources

About